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Abstract. We examined the apoptotic effect of a novel 
Probiotics Fermentation Technology (PFT) kefir grain 
product; PFT is a natural mixture composed primarily of 
Lactobacillus kefiri P-IF, a specific strain of L. kefiri with 
unique growth characteristics. The aim of this study was to 
examine the apoptotic effect of PFT on human multidrug-
resistant (MDR) myeloid leukemia (HL60/AR) cells in vitro 
and explore the mechanistic approach underlying its effect. 
HL60/AR cells were cultured with PFT (0.6-5.0 mg/ml) for 
3 days. The apoptotic effect of PFT was assessed through 
examination of percent apoptosis, caspase 3 activation, Bcl-2 
expression levels and changes in mitochondrial membrane 
potential (MMP). PFT induced apoptosis in HL60/AR cells 
in a dose-dependent manner which was maximal at 67.5% for 
5 mg/ml. Induction of apoptosis was associated with activa-
tion of caspase 3, decreased expression of Bcl-2 and decreased 
polarization of MMP. In addition, PFT showed a unique char-
acteristic of piercing holes in HL60/AR cells, as indicated by 
AFM studies. This hole induction may be responsible for the 
apoptotic effect on cancer cells. These results suggest that 
PFT may act as a potential therapy for the treatment of MDR 
leukemia.
Introduction
Lactic acid bacteria (LAB) have been used throughout history 
to produce fermented food and milk products. In the early 
1900s, biologist Eli Metchinkoff suggested that the intake of 
LAB could increase the life span of humans (1). His findings 
have been verified by many scientists who have found that 
ingesting LAB fermented products provides many benefits for 
maintaining health (2,3). LAB strains present in fermented 
milk are normal components of intestinal microflora and help 
maintain a healthy balance of probiotic bacteria while reducing 
pathogenic bacteria (4,5). In addition to gut maintenance, LAB 
have more recently been tested to treat a variety of diseases 
including Crohn's disease, rheumatoid arthritis and cancer (6).
The idea of treating cancers with LAB is not as recent as 
one might think. Over a century ago, Metchnikoff suggested 
that LAB had a protective effect against colorectal cancer (7). 
However, it is the recent resurgence of research concerning 
the microbiotic influence on human health that has spurred 
researchers to confirm Metchnikoff's findings on the anti-
cancer ability of LAB in animal models and to expand 
understanding of LAB's influence on the cellular environment 
(8-12). Additional research has shown that LAB also exerts 
anticancer activity against other types of cancer such as breast 
and ovarian cancer (13-17).
Conventional treatments for cancer such as chemotherapy 
aim to initiate apoptosis. However, these drugs can be toxic and 
can decrease a cancer patient's quality of life. Therefore, there 
has been an effort to investigate alternative treatments that 
have fewer side effects and improve the health of the patient. 
A recent study has shown that Lactobacillus reuteri enhanced 
tumor necrosis factor (TNF)-induced apoptosis in human 
chronic myeloid leukemia-derived cells (18) and that bacterial 
soluble factors secreted by Lactobacillus casei rhamnosus 
caused induction of apoptosis in human monocytic leukemia-
cell line, THP-1 (19). These data suggest that fermented milk 
products and/or the fermentative bacteria themselves may 
have chemoprotective effects without the toxic side effects of 
conventional therapeutic drugs.
The product we use in this study is a symbiotic microbe of 
lactic acid bacteria and yeasts known as Probiotics Fermentation 
Technology (PFT) kefir grain product. PFT is separated from 
kefir, a popular drink across Eastern and Northern Europe and 
Russia. Kefir has been shown to have various health benefits, 
for example, it protects the intestine against disease-causing 
bacteria (20) and its kefiran component was shown to lower 
high blood pressure and reduce serum cholesterol levels in 
rats (21). PFT mainly contains a unique Lactobacillus kefiri 
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P-IF (L. kefiri P-IF) strain that has a unique DNA sequence 
and shows a 99.6% homology with regular kefiries and similar 
16S ribosome sequence compared with other L. kefiri strains. 
Although strain P-IF shares many common characteristics 
with other L. kefiri strains, P-IF also has many distinct features 
that may contribute to its effectiveness as an anticancer agent 
(Table I) (22). Unlike other L. kefiri strains, P-IF utilizes galac-
tose as a carbon source and produces carbonic acid when its 
growth medium is agitated. Most L. kefiri strains grow in a 
lengthwise-dimensional pattern, however, P-IF grows three-
dimensionally, which is attributed to the unique carbohydrate 
chains on its surface (22).
The results of this study show that PFT possesses the ability 
to pierce holes in MDR human myeloid leukemic (HL60/AR) 
cells, which induces apoptosis in the cancer cells by intrinsic 
(mitochondrial) pathway of apoptosis. This study suggests that 
PFT may exert a therapeutic effect in treating MDR cancers.
Materials and methods
Tumor cell line and culture conditions. Human multidrug-
resistant (MDR) myeloid leukemia (HL60/AR) cells were 
used in the present study. Cells were kindly provided by 
Dr S. Gollapudi at the University of California, Irvine, 
CA, USA. Tumor cells were maintained in our laboratory 
in a complete medium (CM) that consisted of RPMI-1640, 
10% fetal calf serum (FCS), 2 mM glutamine and 100 µg/ml 
streptomycin and penicillin.
Drugs and chemicals. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, 
MO, USA), was employed. 
Probiotics Fermentation Technology (PFT) kefir grain product. 
PFT is a mixture that mainly (~90%) contains a freeze-dried 
form of heat-killed L. kefiri P-IF; it is a specific strain of LAB 
that has a unique DNA sequence and PET scans show a 99.6% 
homology with regular kefiries. Characteristics of L. kefiri P-IF 
are shown in Table I and Fig. 1. PFT also contains ~2-3% each 
of bacterial strain, Lactobacillus kefiri P-IF and Lactobacillus 
kefiri P-B1 and three yeast strains, Kazachstania turicensis, 
Kazachstania unispora and Kluyveromyces marxianus (22). 
PFT was provided by Paitos Co., Ltd. Yokohama, Kanagawa, 
Japan.
Detection of cancer cell viability using propidium iodide. 
HL60/AR cells were cultured in the presence or absence of 
PFT at different concentrations (0, 0.6, 1.25, 2.5 and 5 mg/
ml) for 3 days and the percentage of dead cancer cells was 
examined by the propidium iodide (PI) technique using a 
FACScan flow cytometery. Briefly, PI was added to the cells 
(1x106/ml) to give a final PI concentration of 50 µg/ml. The 
cells were stained for 30 min at room temperature in the dark 
and analyzed by FACScan (Becton-Dickinson, San Jose, CA, 
USA).
Expression of Bcl-2. For detection of Bcl-2, cells were first 
fixed and permeabilized with ice-cold 70% methanol. Cells 
were then stained with FITC-labeled anti-Bcl-2 or isotype 
control (Dako Corp., Carpinteria, CA, USA), washed and 
analyzed by FACScan. The percentage of cells expressing 
Bcl-2 and mean fluorescent intensity (an indicator of density 
of the molecules/cell) was determined.
Intracellular activity of caspase 3. The method for measuring 
intracellular activity of caspase 3 is based on carboxyfluores-
cein labeled fluromethyl ketone (FMK)-peptide inhibitors of 
caspases. These inhibitors are cell permeable and non-toxic. 
Once inside the cells, these inhibitors bind covalently to the 
active caspase. Caspase-positive (+) cells are distinguished 
from caspase-negative (-) cells with the aid of flow cytometry. 
Briefly, cells undergoing apoptosis were loaded with fluores-
cein labeled FAM-DEVD-FMK for caspase 3 (Intergen Co., 
NY, USA). After 1-h incubation, the cells were washed to 
remove unbound caspase and cells that contained bound 
inhibitor were quantified using a FACScan flow cytometer.
Detection of mitochondrial membrane potential (MMP). 
Variations of the mitochondrial transmembrane potential 
∆Ψm during apoptosis were studied using tetramethylrho-
damine ethylester (TMRE, Molecular Probes, Eugene, OR, 
USA). Briefly, after treatment with PFT for 3 days, cancer 
cells (5x105 cells/ml) were incubated with 50 nM TMRE 
for 30 min at 37˚C. The cells were washed with PBS and 
analyzed with FACS Forward, the side scatters were used to 
gate and exclude cellular debris using a FACScan. The cells 
were excited at 488 nm and the emission was collected on 
the FL2 channel. Five thousand cells were analyzed. The 
data were acquired and analyzed using CellQuest software 
(Becton-Dickinson).
AFM imaging. HL60/AR cells (1x106 cells/ml) were cultured 
with PFT (5 mg/ml) for 2 min and 24 h. Results were compared 
Table I. L. kefiri P-IF strain characteristics.
Test P-IF characteristic
Lactobacillis kefiri 99.6% sequence homology
  16S ribosome identification
Cell shape Rod
Gram staining +
Motility Non-motile
Colony growth 3D growtha
Carbon utilization Glucose
  Fructose
  Galactosea
  L-arabinose
  Ribose
  Maltose
  Lactose
  Melibiose
 Gluconate
Acid/gas production Carbonic acid gasa
pH tolerance >4.3 pHa
aCharacteristics not common in other kefiri strains.
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to those of cells without treatment. Cytospin preparations 
(Shandon Southern Inst., Sewickley, PA, USA) of cells were 
air-dried, fixed in 100% MeOH for 5 min and prepared for 
AFM studies. AFM studies were carried out to examine the 
morphological changes associated with PFT treatment of 
HL60/AR cells such as hole induction and membrane blebbing. 
Dimension 5000 AFM (Veeco) under contact mode was used 
to image the HL60/AR cells with Bruker's Sharp Nitride Lever 
(SNL) silicon probes (Veeco). Topographic height images 
were recorded at 512x512 pixels at a scan rate of 0.8 Hz. Image 
processing was performed using SPIPTM Software. Usually an 
MLCT-AFM tip (with a ‘k’ value of 0.03N/m) contributes to 
the broadening effect because of its specific geometry (23).
Statistical analysis. Statistical significance for cell apoptosis 
in Fig. 2 was determined by Student's t-test. Differences were 
considered significant at the p<0.05 level. Statistical analysis 
for flow cytometry was performed by the Kolmogorov-Smirnov 
test using CellQuest Software system. A D-value of >0.2 was 
considered statistically significant.
Results
Effect of PFT on tumor cell survival. We examined the effect 
of PFT on tumor cell survival using propidium iodide and 
FACScan flow cytometry. The data in Fig. 2 demonstrate that 
treatment with PFT increased apoptosis in the cancer cells 
in a dose-dependent manner. Even at a lower concentration 
(0.6 mg/ml), the PFT induced apoptosis in ~30% of the HL60/
AR cells. The percentage of apoptosis continued to increase 
in conjunction with higher concentrations of PFT reaching an 
average of 67.5% apoptosis at 5 mg/ml.
PFT induces activation of caspase 3. To verify activation of 
the apoptotic pathway, the level of caspase 3 activation was 
investigated by treating HL60/AR cells with PFT at varying 
concentrations for 24 h and analyzed using flow cytometry. 
Data depicted in Fig. 3 show that the proportion of cancer cells 
with increased active caspase 3 was higher in PFT-treated 
cells than in control untreated cells. This would suggest that 
pre-exposure of HL60/AR cells to PFT led to increased activa-
tion of the executioner caspase 3.
PFT depolarizes mitochondrial membrane potential (MMP). 
Experiments were carried out to examine the ability of PFT 
Figure 1. L. kefiri P-IF can grow in three dimensions. Electron microscope 
image of L. kefiri P-IF strain. L. kefiri P-IF are rod-shaped bacteria that 
uniquely adhere to one another in all three dimensions.
Figure 2. PFT induces apoptosis of HL60/AR cells. Tumor cells were cultured 
with PFT at different concentrations (0, 0.6, 1.25, 2.5 and 5 mg/ml) and the 
percentage of dead cancer cells was examined by the propidium iodide (PI) 
technique using a FACScan flow cytometry. Data represent the mean ± SD 
of 4 experiments. Statistical analysis compared the concentrations to control 
(0 mg/ml). *p<0.05, **p<0.0005, ***p<0.0001.
Figure 3. PFT induces apoptosis through activation of caspase 3. The activation 
of caspase 3 was determined in cancer cells post-culture with PFT at different 
concentrations (0, 0.6, 1.25 and 2.5 mg/ml). The lines represent cancer cells in 
the absence of PFT (control, purple) and cancer cells treated with PFT at con-
centration of 0.6 mg/ml (green), 1.25 mg/ml (pink), or 2.5 mg/ml (blue). The 
activation of caspase 3 in cells was detected using carboxyfluorescein-labeled 
cell permeable peptide substrate and was analyzed using flow cytometry.
Figure 4. PFT reduces MMP. Tumor cells were cultured with PFT at different 
concentrations (0, 0.6, 1.25 and 2.5 mg/ml) and the MMP was determined 
by flow cytometry using TMRE dye. Decrease in TMRE fluorescence 
indicates loss of membrane potential. PFT depolarized membrane poten-
tial in a dose-dependent manner. Statistical analysis was performed by the 
Kolmogorov-Smirnov test using CellQuest Software System. A D-value >0.2 
is considered statistically significant.
GHONEUM  and  GIMZEWSKI:  INDUCTION OF APOPTOSIS IN CANCER CELLS BY UNIQUE KEFIR CULTURE 833
to disrupt MMP. HL60/AR cells were treated in the presence 
or absence of PFT at varying concentrations and MMP was 
determined by flow cytometry using membrane potential 
sensitive TMRE dye. The data in Fig. 4 show that treatment 
of cells with PFT resulted in a significant decrease in the 
mitochondrial polarization of cancer cells as compared to 
untreated cells.
Expression of Bcl-2. The expression of Bcl-2 was examined to 
determine the anti-apoptotic activity post-treatment of HL60/
AR cells by PFT. Results depicted in Fig. 5 show that treat-
ment with PFT caused a statistically significant decrease in 
expression of Bcl-2 compared to control cancer cells without 
treatment.
AFM studies. AFM studies were carried out to examine the 
morphological changes associated with PFT treatment of 
HL60/AR cells. Results showed a low percentage of the control 
untreated HL60/AR cells with holes, as well as a small number 
of holes per cell (Fig. 6A). When the cancer cells were exposed 
to L. kefiri P-IF (5 mg/ml) for 2 min, we observed an adherence 
of L. kefiri P-IF to the cancer cells (Fig. 6B). Exposure of cancer 
cells to L. kefiri P-IF for a longer time (24 h) resulted in 2.6-fold 
increase in the percentage of cancer cells with holes. Control 
untreated cells showed 17.5% had single holes and 2% had 
multiple holes. However, of the L. kefiri P-IF-treated cells, 42% 
had single holes and 9.5% had multiple holes. Fig. 6C shows 
multiple holes surrounding the nucleus. Some of the holes are 
highly enlarged, as can be seen in Fig. 6D. The holes were 
situated in the cytoplasm and the nucleus. Fig. 6D and E also 
shows that hole induction was associated with membrane bleb-
bing and a decrease in the nuclear to cytoplasmic ratio. These 
morphological changes are considered to be signs of cancer cell 
apoptosis. The holes were further characterized by peak force 
imaging (Figs. 7 and 8), where the variation in size, shape and 
Figure 5. PFT reduces the expression of Bcl-2. HL60/AR cells (1x106 cells/
ml) were cultured with PFT at a concentration of 1.25 mg/ml for 24 h. 
Expression of Bcl-2 was determined by staining the cells with anti-human 
Bcl-2 antibody and by flow cytometry. It is shown as mean fluorescent 
intensity (MCF).
Figure 6. PFT induces holes and membrane blebbing in cancer cells. HL60/AR cells (1x106 cells/ml) were cultured with PFT and the changes were examined 
by AFM. (A) Control untreated cells. (B) Cells treated with 5 mg/ml of PFT for 2 min; note the attachment of cancer cells to L kefiri P-IF (arrowheads). 
(C-E) Cells treated with 5 mg/ml of PFT for 24 h; note the presence of extensive holes surrounding the nucleus. (D) A cancer cell with three large holes (thin 
arrows). (D and E) Membrane blebbing of cancer cells is indicated by thick arrows. Cells were examined using optical imaging.
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depth of the holes was measured. The color intensity indicates 
hole depth, with lighter areas being shallow or flat and darker 
colors indicating depth (Fig. 7). The topography of the cell was 
traced using a cantilever tip. The changes in the vertical move-
ment of the SNL tip were recorded and visualized in graphic 
form as seen in Fig. 8. A decrease along the y-axis indicates 
the presence of a hole on the surface of the cell. During PFT 
treatment, many holes were detected in HL60/AR cells using 
this method of analysis (Fig. 8).
Discussion
In this study, we examined the apoptotic activity of PFT, a 
mixture with the main constituent of L. kefiri P-IF. While 
Figure 7. Hole detection using AFM (peak force imaging). Darker color indicates greater hole depth. Note the variation in hole shape, size and depth. (A and B) 
Several smaller, distinctly circular holes. (C and D) A broad, irregularly shaped, deep indentation. (E and F) A large, circular hole.
Figure 8. Determining the depth of PFT-induced hole formation. The red and blue lines indicate the surface contour of an HL60/AR cell treated with PFT. The arrow 
indicates a large hole detected by the SNL tip and arrowheads indicate smaller holes. This image is representative of many HL60/AR cells during PFT treatment. 
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yogurt consumption and exposure to LAB has been shown 
to exert an inhibitory effect on the growth of different types 
of cancers (9,11,14-17), no study has examined the apoptotic 
effects of LAB against MDR cancer cells nor the possible 
mechanism underlying its effect on these cells. Our results 
show that PFT has the ability to induce an apoptotic effect 
on MDR cancer cells in a dose-dependent manner, which is 
maximal at 67.5% at concentration of 5 mg/ml. This ability of 
PFT holds great potential because the development of MDR 
to chemotherapy by tumor cells presents great obstacles with 
the current treatment options for cancer. Several drugs have 
been developed as sensitizers for chemotherapeutics, such 
as the membrane transporter P-glycoprotein (P-gp) (24,25), 
12-deoxyphorbol 13-phenylacetate (26), probenecid (27) and 
magnetic iron oxide nanoparticles (28,29) but these drugs are 
toxic.
Several studies have shown that LAB exerts antitumor 
activity via several mechanisms. These include the ability of 
LAB for binding mutagens and removing carcinogens from 
colon (30,31), modulation of different arms of the immune 
system such as NK cells, dendritic cells, B cells and T cells 
(32-34) and induction of apoptosis in cancer cells (18,35,36). 
Results of this study showed an interesting phenomenon 
whereby L. kefiri P-IF was able to pierce holes in HL60/AR 
cells. PFT induces apoptosis in HL60/AR cells associated 
with activation of caspase 3, decreased expression of Bcl-2 
and decrease in the polarization of MMP. This suggests that 
these holes appear to be responsible for the induction of 
apoptosis of cancer cells. In addition, AFM studies show that 
cancer cells with holes are correlated with signs of apoptosis 
such as membrane blebbing and decrease in the nuclear 
to cytoplasmic ratio. The mechanism by which uptake of 
L. kefiri P-IF induces an apoptotic effect on cancer cells may 
involve [Ca2+]I. Our earlier studies showed that human breast 
cancer MDA-MB-231 cells underwent apoptosis following 
phagocytosis of heat-killed yeast S. cerevisiae (37) by a 
mechanism that involved the elevation of [Ca2+]I. This was 
evidenced by an increase of [Ca2+]I post-uptake of yeast and 
also in the inhibition of apoptosis post-addition of 2-aminoe-
thoxydiphenyl borate (2APB), a pharmacological inhibitor of 
Ca2+ release from the endoplasmic reticulum. We believe that 
the uptake of L. kefiri P-IF by cancer cells may be responsible 
for the apoptotic effect by this agent.
Hole piercing has been observed with nanoparticles such 
as nickel (38) and DPV576, a mixture of nanodiamond and 
nanoplatinum in liquid (39). It is noteworthy that the hole 
piercing ability of DPV576 has been associated with reversing 
drug resistance in HL60/AR cancer cells by increasing the 
accumulation of chemotherapeautic drugs such as daunoru-
bicin inside cancer cells (39). Therefore, we believe that hole 
induction by L. kefiri P-IF may likewise facilitate the uptake 
and accumulation of chemotherapeutic drugs by MDR cancer 
cells, in a manner similar to DPV576 nanoparticles. This is an 
area for future study.
Vacuoles appear in the cancer cells apparently due to the 
cells ability to phagocytize microorganisms, such as bacteria 
and yeast (40-43) and other cells, including: erythrocytes, 
lymphocytes and neutrophils (44-46). Furthermore, research 
has also revealed the cannibalistic ability of tumor cells to 
phagocytize other cancer cells (47). In the present study, we 
observed that cancer cells treated with L. kefiri P-IF revealed 
a 2.6-fold increase in the percentage of cells with holes as 
compared to control untreated HL60/AR cells. This increase 
was observed in both cancer cells with single as well as 
multiple holes, which were situated in the cytoplasm and in 
the nucleus.
The unique properties of the L. kefiri P-IF strain may 
account for its ability to induce apoptosis in the MDR HL60/
AR leukemic cell line. The specific three-dimensional growth 
of the P-IF colony indicates that the surface proteoglycans 
differ from other L. kefiri strains (22). The cell surface of 
bacteria and other microorganisms are composed of varying 
polysaccharide-peptide complexes that have been shown to 
have specific stimulatory effects on host cells that can be 
beneficial or inhibitory for cell growth (48-50). Further inves-
tigation into the unique cell wall components and attributes 
of L. kefiri P-IF could contribute to a better understanding of 
the apoptotic induction by cell surface proteoglycans. While 
not investigated in this study, L. kefiri P-IF has the ability to 
survive at a low pH, indicating that the P-IF strain remains 
viable as it travels through the stomach into the intestine, 
allowing it to continue to grow and provide a protective 
effect. Some of the protective effects of the P-IF strain may 
come from its ability to metabolize galactose. High levels of 
galactose can cause toxicity which could lead to mutations 
and health problems (51). The presence of L. kefiri P-IF in 
the gut may help to prevent damaging levels of galactose (52). 
This property warrants future investigation for prevention 
and maintenance of general health.
L. kefiri P-IF has been shown to be a non-toxic agent. 
Results of earlier studies in mice treated with L. kefiri P-IF 
showed that no macroscopic or histopathological abnormali-
ties were detected in different organs post-treatment and no 
changes in the body weight as compared with control untreated 
mice (53).
In conclusion, L. kefiri P-IF represents a novel symbiotic 
microbe culture that exerts an apoptotic effect on HL60/AR 
cells by a mechanism that may involve piercing holes in the 
cellular membrane of cancer cells. L. kefiri P-IF may represent 
a new class of adjuvants that could be used to improve the 
treatment of MDR leukemia.
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